Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by thrombosis, pregnancy morbidity, or non-thrombotic manifestations in patients with persistently positive antiphospholipid antibodies (aPL). Conventional treatment strategies of antiphospholipid syndrome focuses on antithrombotic agents, however they are usually not effective for microvascular and non-thrombotic manifestations of aPL. In parallel to our increased understanding of the mechanisms of aPL-mediated clinical events, immunosuppression has been increasingly used in aPL-positive patients. This review focuses on the role of potential targeted immunosuppressive treatments in APS (B-cell inhibition, complement inhibition, mechanistic target of rapamycin inhibition, and traditional rheumatologic disease–modifying agents including hydroxychloroquine) and future perspectives.

抗磷脂综合征 (APS) 是一种全身性自身免疫性疾病，其特征是抗磷脂抗体 (aPL) 持续阳性的患者出现血栓形成、妊娠发病或非血栓形成表现。抗磷脂综合征的常规治疗策略侧重于抗血栓药物，但它们通常对 aPL 的微血管和非血栓表现无效。随着我们对 aPL 介导的临床事件机制的了解不断加深，免疫抑制已越来越多地用于 aPL 阳性患者。本综述侧重于潜在的靶向免疫抑制治疗在 APS 中的作用（B 细胞抑制、补体抑制、雷帕霉素抑制的机制靶点、